|   | |
| Legal status | |
|---|---|
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H12ClFN4 | 
| Molar mass | 326.76 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Flualprazolam is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It was first synthesised in 1976, [2] but was never marketed. It can be seen as the triazolo version of fludiazepam. It has subsequently been sold as a designer drug, [3] [4] [5] [6] first being definitively identified as such in Sweden in 2018. [7] [8] It can be described as the 2'-fluoro derivative of alprazolam or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects. [9] [10] [11] [12] [13]
Flualprazolam is banned in Sweden and illegal in the UK. [14] In December 2019, the World Health Organization recommended flualprazolam for international scheduling as a Schedule IV medication under the Convention on Psychotropic Substances. [15]
In the United States, Oregon and Virginia have placed Flualprazolam into Schedule I. [16] On 23 December 2022, the DEA announced it had begun consideration on the matter of placing Flualprazolam under temporary Schedule I status. [17] Later on 25 July 2023, the DEA published a pre-print notice that Flualprazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025. [18] On 25 July 2025, and effective the following day, the DEA extended the temporary scheduling until 26 July 2026. [19]